A Dark Vector Cognition product

Verisk Analytics 10-Q 2025-06-30

VRSK · CIK 1442145 · Form 10-Q · Period ended June 30, 2025 · Filed July 30, 2025

Revenue rose 7.8% to $773 million. Operating margin was 45.9%, against 44.5% a year earlier. Net income was $253 million.

8 sections, 156K characters. Original on sec.gov · ·

Risk FactorsBusiness

Key numbers
MeasureQuarter ended Jun 30, 2025Quarter ended Jun 30, 2024Change
Revenue$773M$717M+7.8%
Operating income$354M$319M+11.2%
Net income$253M$308M-17.8%
Diluted EPS$1.81$2.15-15.8%
Free cash flow*$189M$154M+22.6%
Cash and equivalents$629Mn/an/a
Operating margin*45.9%44.5%+1.4 pts

From the XBRL facts tagged to this filing; both columns are as reported in this filing. * Computed by filings.tools: free cash flow is operating cash flow less capital spending; operating margin is operating income over revenue.

The 54 tables in this filing as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Cover and table of contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2025

OR

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-34480

VERISK ANALYTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware26-2994223
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
545 Washington Boulevard
Jersey City
NJ07310-1686
(Address of principal executive offices)(Zip Code)

(201) 469-3000

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange where registered
Common Stock $.001 par valueVRSKNASDAQ Global Select Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of July 25, 2025, there were 139,714,971 shares outstanding of the registrant's Common Stock, par value $.001.

Verisk Analytics, Inc.

Index to Form 10-Q

Table of Contents

Page Number
PART I — FINANCIAL INFORMATION
Item 1. Financial Statements (unaudited)
Condensed Consolidated Balance Sheets1
Condensed Consolidated Statements of Operations2
Condensed Consolidated Statements of Comprehensive Income3
Condensed Consolidated Statements of Changes in Stockholders’ Equity4
Condensed Consolidated Statements of Cash Flows6
Notes to Condensed Consolidated Financial Statements7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations25
Item 3. Quantitative and Qualitative Disclosures About Market Risk35
Item 4. Controls and Procedures35
PART II — OTHER INFORMATION
Item 1. Legal Proceedings36
Item 1A. Risk Factors36
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds36
Item 3. Defaults Upon Senior Securities37
Item 4. Mine Safety Disclosures37
Item 5. Other Information37
Item 6. Exhibits37
SIGNATURES39
Exhibit 31.1
Exhibit 31.2
Exhibit 32.1

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

VERISK ANALYTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

June 30, 2025December 31, 2024
(in millions, except for share and per share data)
ASSETS:
Current assets:
Cash and cash equivalents$628.7$291.2
Accounts receivable, net of allowance for doubtful accounts of $31.1 and $22.5, respectively612.0434.4
Prepaid expenses78.972.8
Income taxes receivable29.583.3
Other current assets28.329.9
Total current assets1,377.4911.6
Noncurrent assets:
Fixed assets, net593.1605.9
Operating lease right-of-use assets, net148.8156.0
Intangible assets, net387.9392.4
Goodwill1,809.41,726.6
Deferred income tax assets37.334.3
Other noncurrent assets441.0437.9
Total assets$4,794.9$4,264.7
LIABILITIES AND STOCKHOLDERS’ EQUITY:
Current liabilities:
Accounts payable and accrued liabilities$175.6$249.8
Short-term debt and current portion of long-term debt17.0514.2
Deferred revenues671.0447.2
Operating lease liabilities27.826.0
Income taxes payable8.01.7
Total current liabilities899.41,238.9
Noncurrent liabilities:
Long-term debt3,233.22,546.9
Deferred income tax liabilities180.5191.6
Operating lease liabilities149.8158.7
Other noncurrent liabilities19.423.6
Total liabilities4,482.34,159.7
Commitments and contingencies (Note 16)
Stockholders’ equity:
Common stock, $.001 par value; 2,000,000,000 shares authorized; 544,003,038 shares issued; 139,700,834 and 140,414,637 shares outstanding, respectively0.10.1
Additional paid-in capital3,080.32,994.0
Treasury stock, at cost, 404,302,204 and 403,588,401 shares, respectively(10,397.6)(10,062.4)
Retained earnings7,513.27,153.4
Accumulated other comprehensive income115.715.0
Total Verisk stockholders' equity311.7100.1
Noncontrolling interests0.94.9
Total stockholders’ equity312.6105.0
Total liabilities and stockholders’ equity$4,794.9$4,264.7

The accompanying notes are an integral part of these condensed consolidated financial statements.

VERISK ANALYTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
(in millions, except for share and per share data)
Revenues$772.6$716.8$1,525.6$1,420.8
Operating expenses:
Cost of revenues (exclusive of items shown separately below)229.5219.4460.3447.2
Selling, general and administrative106.5101.5215.4194.4
Depreciation and amortization of fixed assets66.059.0133.4116.4
Amortization of intangible assets16.318.232.136.7
Total operating expenses, net418.3398.1841.2794.7
Operating income354.3318.7684.4626.1
Other income (expense):
Net gain on early extinguishment of debt—3.6—3.6
Investment gain9.199.811.796.5
Interest expense, net(35.5)(29.1)(71.8)(58.0)
Total other (expense) income, net(26.4)74.3(60.1)42.1
Income before income taxes327.9393.0624.3668.2
Provision for income taxes(74.6)(85.2)(138.7)(141.0)
Net income253.3307.8485.6527.2
Less: Net loss attributable to noncontrolling interests—0.3—0.5
Net income attributable to Verisk$253.3$308.1$485.6$527.7
Basic net income per share attributable to Verisk:$1.81$2.16$3.47$3.69
Diluted net income per share attributable to Verisk:$1.81$2.15$3.45$3.67
Weighted-average shares outstanding:
Basic139,818,324142,705,508140,056,221143,001,836
Diluted140,339,539143,293,222140,639,547143,633,378

The accompanying notes are an integral part of these condensed consolidated financial statements.

VERISK ANALYTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)

Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
(in millions)
Net income$253.3$307.8$485.6$527.2
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment69.0(1.4)99.3(15.7)
Pension and postretirement liability adjustment0.90.91.81.7
Total other comprehensive income (loss)69.9(0.5)101.1(14.0)
Comprehensive income323.2307.3586.7513.2
Less: Comprehensive loss (income) attributable to noncontrolling interests—0.2(0.4)(0.9)
Comprehensive income attributable to Verisk$323.2$307.5$586.3$512.3

The accompanying notes are an integral part of these condensed consolidated financial statements.

VERISK ANALYTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (UNAUDITED)

For The Three Months Ended June 30, 2025 and 2024

| | | Common Stock Issued | | | | Par Value | | | | Additional Paid-in Capital | | | | Treasury Stock | | | | **_Retained

Showing the first 8K of 96K characters. Open the full section

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

| --- | --- |

The following discussion should be read in conjunction with our historical financial statements and the related notes included in our annual report on Form 10-K ("2024 10-K") dated and filed with the Securities and Exchange Commission on February 26, 2025. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those discussed in or implied by any of the forward-looking statements as a result of various factors, including but not limited to those listed under "Risk Factors" and "Special Note Regarding Forward Looking Statements" in our 2024 Form 10-K and those listed under Item 1A in Part II of this quarterly report on Form 10-Q.

We are a leading data analytics provider serving clients in the insurance markets. Using advanced technologies to collect and analyze billions of records, we draw on unique data assets and deep domain expertise to provide innovations that may be integrated into client workflows. We offer predictive analytics and decision support solutions to clients in rating, underwriting, claims, catastrophe and weather risk, global risk analytics, and many other fields. In the U.S., and around the world, we help clients protect people, property, and financial assets.

Our clients use our solutions to make better decisions about risk and opportunities with greater efficiency and discipline. We refer to these products and services as “solutions” due to the integration among our services and the flexibility that enables our clients to purchase components or the comprehensive package. These solutions take various forms, including data, statistical models, or tailored analytics, all designed to allow our clients to make more logical decisions. We believe our solutions for analyzing risk positively impact our clients’ revenues and help them better manage their costs.

Executive Summary

Key Performance Metrics

Revenue growth. We use year-over-year revenue growth as a key performance metric. We assess revenue growth based on our ability to generate increased revenue through increased sales to existing customers, sales to new customers, sales of new or expanded solutions to existing and new customers, and strategic acquisitions of new businesses.

We use year-over-year EBITDA growth as metrics to measure our performance. EBITDA and EBITDA margin are non-GAAP financial measures. EBITDA is defined as net income before interest expense, provision for income taxes, and depreciation and amortization of fixed and intangible assets. We calculate EBITDA margin as EBITDA divided by revenues. The respective nearest applicable GAAP financial measures are net income and net income margin. Although EBITDA is a non-GAAP financial measure, EBITDA is frequently used by securities analysts, lenders, and others in their evaluation of companies; EBITDA has limitations as an analytical tool, and should not be considered in isolation, or as a substitute for an analysis of our operating income, net income, or cash flow from operating activities reported under GAAP. Management uses EBITDA and EBITDA margin in conjunction with traditional GAAP operating performance measures as part of its overall assessment company performance. We believe these measures are useful and meaningful because they help us allocate resources, make business decisions, allow for greater transparency regarding our operating performance, and facilitate period-to-period comparisons. Some of these limitations involved in the use of EBITDA are:

  • EBITDA does not reflect our cash expenditures, or future requirements for capital expenditures or contractual commitments.

  • EBITDA does not reflect changes in, or cash requirements for, our working capital needs.

  • Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized often will have to be replaced in the future and EBITDA does not reflect any cash requirements for such replacements.

  • Other companies in our industry may calculate EBITDA differently than we do, limiting its usefulness as a comparative measure.

EBITDA growth. We use EBITDA growth as a measure of our ability to balance the size of revenue growth with cost management and investing for future growth. EBITDA growth allows for greater transparency regarding our operating performance and facilitate period-to-period comparison.

EBITDA margin. We use EBITDA margin as a performance measure to assess segment performance and scalability of our business. We assess EBITDA margin based on our ability to increase revenues while controlling expense growth.

Revenues

We earn revenues through agreements for hosted subscriptions, advisory/consulting services, and for transactional solutions, recurring and non-recurring. Subscriptions for our solutions are generally paid in advance of rendering services either quarterly or in full upon commencement of the subscription period, which is usually for one year and automatically renewed each year. As a result, the timing of our cash flows generally precedes our recognition of revenues and income and our cash flow from operations tends to be higher in the first quarter as we receive subscription payments. Examples of these arrangements include subscriptions that allow our customers to access our standardized coverage language, our claims fraud database, or our actuarial services throughout the subscription period. In general, we experience minimal revenue seasonality within the business. For the six months ended June 30, 2025 and 2024, approximately 83% and 81% of our insurance revenues were derived from hosted subscriptions through agreements (generally one to five years) for our solutions, respectively.

We also provide advisory/consulting services, which help our customers get more value out of our analytics and their subscriptions. In addition, certain of our solutions are paid for by our customers on a transactional basis, recurring and non-recurring. For example, we have solutions that allow our customers to access property-specific rating and underwriting information to price a policy on a commercial building, or compare a P&C insurance or a workers' compensation claim with information in our databases, or use our repair cost estimation solutions on a case-by-case basis. For the six months ended June 30, 2025 and 2024, approximately 17% and 19% of our insurance revenues were derived from providing transactional and advisory/consulting solutions, respectively.

Operating Costs and Expenses

Personnel expenses are the major component of both our cost of revenues and selling, general and administrative expenses. Personnel expenses, which represented approximately 56% and 58% of our total operating expenses (excluding gains/losses related to dispositions) for the six months ended June 30, 2025 and 2024, respectively, include salaries, benefits, incentive compensation, equity compensation costs, sales commissions, employment taxes, recruiting costs, and outsourced temporary agency costs.

We assign personnel expenses between two categories, cost of revenues and selling, general and administrative expense, based on the actual costs associated with each employee. We categorize employees who maintain our solutions as cost of revenues, and all other personnel, including executive managers, salespeople, marketing, business development, finance, legal, human resources, and administrative services, as selling, general and administrative expenses. A significant portion of our other operating costs, such as facilities and communications, is also either captured within cost of revenues or selling, general and administrative expenses based on the nature of the work being performed.

While we expect to grow our headcount over time to take advantage of our market opportunities, we believe that the economies of scale in our operating model will allow us to grow our personnel expenses at a lower rate than revenues. Historically, our EBITDA margin has improved because we have been able to increase revenues without a proportionate corresponding increase in expenses. However, part of our corporate strategy is to invest in new solutions and new businesses, which may offset margin expansion.

Cost of Revenues. Our cost of revenues consists primarily of personnel expenses. Cost of revenues also includes the expenses associated with the acquisition, disposition and verification of data, the maintenance of our existing solutions, and the development and enhancement of our next-generation solutions. Our cost of revenues excludes depreciation and amortization.

Selling, General and Administrative Expenses. Our selling, general and administrative expenses consist primarily of personnel costs. A portion of the other costs such as facilities, insurance, and communications are also allocated to selling, general and administrative expenses based on the nature of the work being performed by the employee. Our selling, general and administrative expenses exclude depreciation and amortization.

Condensed Consolidated Results of Operations

Three Months EndedSix Months Ended
June 30,PercentageJune 30,Percentage
20252024Change20252024Change
(in millions, except for share and per share data)
Statement of income data:
Revenues:
Insurance$772.6$716.87.8%$1,525.6$1,420.87.4%
Operating expenses:
Cost of revenues (exclusive of items shown separately below)229.5219.44.6%460.3447.22.9%
Selling, general and administrative106.5101.54.9%215.4194.410.8%
Depreciation and amortization of fixed assets66.059.011.9%133.4116.414.6%
Amortization of intangible assets16.318.2(10.4)%32.136.7(12.5)%
Total operating expenses, net418.3398.15.1%841.2794.75.9%
Operating income354.3318.711.2%684.4626.19.3%
Other income (expense):
Net gain on early extinguishment of debt—3.6(100.0)%—3.6(100.0)%
Investment gain9.199.8(90.9)%11.796.5(87.9)%
Interest expense, net(35.5)(29.1)22.0%(71.8)(58.0)23.8%
Total other (expense) income, net(26.4)74.3(135.5)%(60.1)42.1(242.8)%
Income before income taxes327.9393.0(16.6)%624.3668.2(6.6)%
Provision for income taxes(74.6)(85.2)(12.4)%(138.7)(141.0)(1.6)%
Net income253.3307.8(17.7)%485.6527.2(7.9)%
Less: Net loss attributable to noncontrolling interests—0.3(100.0)%—0.5(100.0)%
Net income attributable to Verisk$253.3$308.1(17.8)%$485.6$527.7(8.0)%
Basic net income per share attributable to Verisk:$1.81$2.16(16.2)%$3.47$3.69(6.0)%
Diluted net income per share attributable to Verisk:$1.81$2.15(15.8)%$3.45$3.67(6.0)%
Cash dividends declared per share (1):$0.45$0.3915.4%$0.90$0.7815.4%
Weighted average shares outstanding:
Basic139,818,324142,705,508(2.0)%140,056,221143,001,836(2.1)%
Diluted140,339,539143,293,222(2.1)%140,639,547143,633,378(2.1)%
The financial operating data below sets forth the information we believe is useful for investors in evaluating our overall financial performance:
Other data:
EBITDA(2)$445.7$499.3(10.7)%$861.6$879.3(2.0)%
The following is a reconciliation of net income to EBITDA:
Net income$253.3$307.8(17.7)%$485.6$527.2(7.9)%
Depreciation and amortization of fixed assets and intangible assets82.377.26.6%165.5153.18.1%
Interest expense35.529.122.0%71.858.023.8%
Provision for income taxes74.685.2(12.4)%138.7141.0(1.6)%
EBITDA$445.7$499.3(10.7)%$861.6$879.3(2.0)%
(1)Cash dividends declared per share is calculated by the aggregate cash dividends declared in a fiscal quarter divided by the shares issued and outstanding. See Note 11. of our condensed consolidated financial statements included in this interim report on Form 10-Q.
(2)EBITDA is a financial measure that management uses to evaluate the performance of our segments. "EBITDA" is defined as net income before interest expense, provision for income taxes, and depreciation and amortization of fixed and intangible assets. See Note 14. of our condensed consolidated financial statements included in this quarterly report on Form 10-Q. Although EBITDA is a non-GAAP financial measure, EBITDA is frequently used by securities analysts, lenders, and others in their evaluation of companies. EBITDA has limitations as an analytical tool, and should not be considered in isolation, or as a substitute for an analysis of our operating income, net income, or cash flows from operating activities reported under GAAP. Management uses EBITDA in conjunction with GAAP operating performance measures as part of its overall assessment of company performance. Some of these limitations are:
•EBITDA does not reflect our cash expenditures, or future requirements for capital expenditures or contractual commitments;
•EBITDA does not reflect changes in, or cash requirements for, our working capital needs;
•Although depreciation and amortization are noncash charges, the assets being depreciated and amortized often will have to be replaced in the future and EBITDA does not reflect any cash requirements for such replacements; and
•Other companies in our industry may calculate EBITDA differently than we do, limiting its usefulness as a comparative measure.

Consolidated Results of Operations

Three Months Ended June 30, 2025 Compared to Three Months Ended June 30, 2024

Revenues

Revenues were $772.6 million for the three months ended June 30, 2025, compared to $716.8 million for the three months ended June 30, 2024, an increase of $55.8 million or 7.8%. Our underwriting revenue increased $42.1 million or 8.3%. Our claims revenue increased $13.7 million or 6.6%.

Our revenue by category for the periods presented is set forth below:

Three Months Ended June 30,Percentage change excluding
20252024Percentage changerecent acquisitions/dispositions
(in millions)
Underwriting$549.6$507.58.3%9.1%
Claims223.0209.36.6%6.6%
Total Insurance$772.6$716.87.8%8.4%

Our recent acquisition (Simplitium within the claims category of the Insurance segment) and dispositions (Atmospheric and Environmental Research ('AER') within the underwriting category of our Insurance segment) resulted in a net decrease in revenue of $3.8 million, while the remaining Insurance revenues increased $59.6 million or 8.4%. Our underwriting revenue increased $45.9 million or 9.1%, primarily due to an annual increase in prices derived from continued enhancements to the models and content of the solutions within our forms, rules and loss cost services, as well as selling expanded solutions to new and existing customers within extreme event solutions. In addition, specialty business and life solutions contributed to the growth. Our claims revenue increased $13.7 million or 6.6%, primarily due to solid growth in anti-fraud solutions and property estimating solutions.

Cost of Revenues

Cost of revenues was $229.5 million for the three months ended June 30, 2025 compared to $219.4 million for the three months ended June 30, 2024, an increase of $10.1 million or 4.6%. Our recent acquisition and disposition accounted for a decrease of $2.6 million in cost of revenues. The remaining increase of $12.7 million or 5.9% was primarily due to salaries and employee benefits of $8.7 million, bad debt expense of $2.8 million, information technology expenses of $2.1 million, professional consulting fees of $1.3 million, and rent expense of $0.6 million, partially offset by a reduction in data costs of $1.0 million, and other operating costs of $1.8 million.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were $106.5 million for the three months ended June 30, 2025 compared to $101.5 million for the three months ended June 30, 2024, an increase of $5.0 million or 4.9%. Our recent acquisition and disposition accounted for a decrease of $1.0 million in selling, general, and administrative expenses. The remaining increase of $6.0 million or 6.1% was primarily due to salaries and employee benefits of $6.1 million, information technology expense of $1.4 million, rent expense of $1.0 million, and travel expenses of $0.6 million, partially offset by professional consulting fees of $2.1 million, insurance expense of $0.7 million, and other operating costs of $0.3 million.

Depreciation and Amortization of Fixed Assets

Depreciation and amortization of fixed assets were $66.0 million for the three months ended June 30, 2025 compared to $59.0 million for the three months ended June 30, 2024, an increase of $7.0 million or 11.9%. The increase was primarily due to internally developed software projects that were completed and placed into service.

Amortization of Intangible Assets

Amortization of intangible assets was $16.3 million for the three months ended June 30, 2025 compared to $18.2 million for the three months ended June 30, 2024, a decrease of $1.9 million or 10.4%. The decrease was primarily due to intangible assets that were fully amortized.

Net Gain on Early Extinguishment of Debt

Net gain on early extinguishment of debt was $3.6 million for the three months ended June 30, 2024 due to a cash tender offer of $400.0 million aggregate principal amount of our 2025 Senior Notes that was completed on June 7, 2024.

Investment Gain

Investment gain was $9.1 million for the three months ended June 30, 2025 compared to $99.8 million for the three months ended June 30, 2024, a decrease of $90.7 million. The decrease was primarily due to the net gains realized in the prior year associated with the settlement of retained interests related to the prior sales of our healthcare business in 2016 and our specialized markets business in 2022, partially offset by the impact of foreign currencies associated with transactions in the normal course of business.

Interest Expense, net

Interest expense, net was $35.5 million for the three months ended June 30, 2025 compared to $29.1 million for the three months ended June 30, 2024, an increase of $6.4 million or 22.0%. The increase was primarily driven by interest expense related to the issuance of our 2035 Senior Notes, partially offset by the repayment of our 2025 Senior Notes and higher interest income for the three months ended June 30, 2025.

Provision for Income Taxes

The provision for income taxes was $74.6 million and the effective tax rate was 22.7% for the three months ended June 30, 2025, compared to $85.2 million and 21.7% for the three months ended June 30, 2024. The increase in the effective tax rate was primarily due to a nonrecurring tax benefit recognized in the prior period. The difference between statutory tax rates and our effective tax rate is primarily due to state and local taxes, partially offset by tax benefits attributable to equity compensation.

Net Income Margin

Net income was $253.3 million for the three months ended June 30, 2025 compared to $307.8 million for the three months ended June 30, 2024. The net income margin was 32.8% for the three months ended June 30, 2025 compared to 42.9% for the three months ended June 30, 2024. The decrease in net income margin was primarily driven by net gains realized in the prior year associated with the settlement of retained interests related to the prior sales of our healthcare business in 2016 and our specialized markets business in 2022, and a net gain on the early extinguishment of debt in the prior year, partially offset by the impact of foreign currencies associated with transactions in the normal course of business.

EBITDA Margin [1]

EBITDA was $ 445.7 million for the three months ended June 30, 2025 compared to $ 499.3 million for the three months ended June 30, 2024. The EBITDA margin for our consolidated results was 57.7% for the three months ended June 30, 2025 compared to 69.7% for the three months ended June 30, 2024. The decrease in EBITDA margin was primarily driven by net gains realized in the prior year associated with the settlement of retained interests related to the prior sales of our healthcare business in 2016 and our specialized markets business in 2022, and a net gain on the early extinguishment of debt in the prior year, partially offset by the impact of foreign currencies associated with transactions in the normal course of business.

Consolidated Results of Operations

Six Months Ended June 30, 2025 Compared to Six Months Ended June 30, 2024

Revenues

Revenues were $1,525.6 million for the six months ended June 30, 2025, compared to $1,420.8 million for the six months ended June 30, 2024, an increase of $104.8 million or 7.4%. Our underwriting revenue increased $75.7 million or 7.5%. Our claims revenue increased $29.1 million or 7.0%.

Our revenue by category for the periods presented is set forth below:

Six Months Ended June 30,Percentage change excluding
20252024Percentage changerecent acquisitions/dispositions
(in millions)
Underwriting$1,081.6$1,005.97.5%8.5%
Claims444.0414.97.0%7.0%
Total Insurance$1,525.6$1,420.87.4%8.0%

Our recent acquisition (Rocket and Simplitium within the claims category of the Insurance segment) and dispositions (AER within the underwriting category of our Insurance segment) resulted in a net decrease in revenue of $8.4 million, while the remaining Insurance revenues increased $113.2 million or 8.0%. Our underwriting revenue increased $84.3 million or 8.5%, primarily due to an annual increase in prices derived from continued enhancements to the models and content of the solutions within our forms, rules and loss cost services, as well as selling expanded solutions to new and existing customers within extreme event solutions. In addition, specialty business and life solutions contributed to the growth. Our claims revenue increased $28.9 million or 7.0%, primarily due to solid growth in anti-fraud solutions and property estimating solutions.

Cost of Revenues

Cost of revenues was $460.3 million for the six months ended June 30, 2025 compared to $447.2 million for the six months ended June 30, 2024, an increase of $13.1 million or 2.9%. Our recent acquisition and disposition accounted for a decrease of $6.3 million in cost of revenues. The remaining increase of $19.4 million or 4.4% was primarily due to salaries and employee benefits of $12.0 million, information technology expenses of $5.5 million, and bad debt expense of $5.0 million, partially offset by a reduction in professional consulting fees of $1.6 million, rent expense of $0.3 million, and other operating costs of $1.2 million.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were $215.4 million for the six months ended June 30, 2025 compared to $194.4 million for the six months ended June 30, 2024, an increase of $21.0 million or 10.8%. Our recent acquisition and disposition accounted for a decrease of $1.8 million in selling, general, and administrative expenses. The remaining increase of $22.8 million or 11.9% was primarily due to salaries and employee benefits of $10.9 million, professional consulting fees of $7.0 million, information technology expense of $1.9 million, rent expense of $1.8 million, and travel expenses of $1.5 million, partially offset by a reduction in insurance expense of $0.3 million.

Depreciation and Amortization of Fixed Assets

Depreciation and amortization of fixed assets were $133.4 million for the six months ended June 30, 2025 compared to $116.4 million for the six months ended June 30, 2024, an increase of $17.0 million or 14.6%. The increase was primarily due to internally developed software projects that were completed and placed into service.

Amortization of Intangible Assets

Amortization of intangible assets was $32.1 million for the six months ended June 30, 2025 compared to $36.7 million for the six months ended June 30, 2024, a decrease of $4.6 million or 12.5%. The decrease was primarily due to intangible assets that were fully amortized of $4.9 million, partially offset by the amortization of intangible assets related to our recent acquisitions of $0.3 million.

Net Gain on Early Extinguishment of Debt

Net gain on early extinguishment of debt was $3.6 million for the six months ended June 30, 2024 due to a cash tender offer of $400.0 million aggregate principal amount of our 2025 Senior Notes that was completed on June 7, 2024.

Investment Gain

Investment gain was $11.7 million for the six months ended June 30, 2025 compared to $96.5 million for the six months ended June 30, 2024, a decrease of $84.8 million. The decrease was primarily due to the net gains realized in the prior year associated with the settlement of retained interests related to the prior sales of our healthcare business in 2016 and our specialized markets business in 2022, partially offset by the impact of foreign currencies associated with transactions in the normal course of business.

Interest Expense, net

Interest expense, net was $71.8 million for the six months ended June 30, 2025 compared to $58.0 million for the six months ended June 30, 2024, an increase of $13.8 million or 23.8%. The increase was primarily driven by interest expense related to the issuance of our 2035 Senior Notes, partially offset by the repayment of our 2025 Senior Notes and increased interest income for the six months ended June 30, 2025.

Provision for Income Taxes

The provision for income taxes was $138.7 million and the effective tax rate was 22.2% for the six months ended June 30, 2025, compared to $141.0 million and 21.1% for the six months ended June 30, 2024. The increase in the effective tax rate was primarily due to a nonrecurring tax benefit recognized in the prior period. The difference between statutory tax rates and our effective tax rate is primarily due to state and local taxes, partially offset by tax benefits attributable to equity compensation.

Net Income Margin

Net income was $485.6 million for the six months ended June 30, 2025 compared to $527.2 million for the six months ended June 30, 2024. The net income margin was 31.8% for the six months ended June 30, 2025 compared to 37.1% for the six months ended June 30, 2024. The decrease in net income margin was primarily driven by net gains realized in the prior year associated with the settlement of retained interests related to the prior sales of our healthcare business in 2016 and our specialized markets business in 2022, and a net gain on the early extinguishment of debt in the prior year, partially offset by the impact of foreign currencies associated with transactions in the normal course of business.

EBITDA Margin [1]

EBITDA was $ 861.6 million for the six months ended June 30, 2025 compared to $ 879.3 million for the six months ended June 30, 2024. The EBITDA margin for our consolidated results was 56.5% for the six months ended June 30, 2025 compared to 61.9% for the six months ended June 30, 2024. The decrease in EBITDA margin was primarily driven by net gains realized in the prior year associated with the settlement of retained interests related to the prior sales of our healthcare business in 2016 and our specialized markets business in 2022, and a net gain on the early extinguishment of debt in the prior year, partially offset by the impact of foreign currencies associated with transactions in the normal course of business.

[1] Note: Consolidated EBITDA margin, a non-GAAP measure, is calculated as a percentage of consolidated revenue. A reconciliation from net income to EBITDA is presented in the table below.

Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
TotalTotalTotalTotal
Net income$253.3$307.8$485.6$527.2
Depreciation and amortization of fixed assets66.059.0133.4116.4
Amortization of intangible assets16.318.232.136.7
Interest expense35.529.171.858.0
Provision for income taxes74.685.2138.7141.0
EBITDA$445.7$499.3$861.6$879.3
Revenue$772.6$716.8$1,525.6$1,420.8
EBITDA Margin57.7%69.7%56.5%61.9%

Liquidity and Capital Resources

As of June 30, 2025 and December 31, 2024, we had cash and cash equivalents and available-for-sale securities totaling $630.0 million and $292.5 million, respectively. We maintain our cash and cash equivalents in higher credit quality financial institutions in order to limit the amount of credit exposure. As of June 30, 2025 and December 31, 2024, a vast majority of our domestic cash and cash equivalents is with TD Bank, N.A., and JPMorgan Chase N.A. Subscriptions for our solutions are billed and generally paid in advance of rendering services either quarterly or in full upon commencement of the subscription period, which is usually for one year. Subscriptions are automatically renewed at the beginning of each calendar year. We have historically generated significant cash flows from operations. As a result of this factor, as well as the availability of funds under our Credit Facility, we expect that we will have sufficient cash to meet our working capital and capital expenditure needs and to fuel our future growth plans.

We have historically managed the business with a working capital deficit due to the fact that, as described above, we offer our solutions and services primarily through annual subscriptions or long-term contracts, which are generally prepaid quarterly or annually in advance of the services being rendered. When cash is received for prepayment of invoices, we record an asset (cash and cash equivalents) on our balance sheet with the offset recorded as a current liability (deferred revenues). This current liability is deferred revenue that does not require a direct cash outflow since our customers have prepaid and are obligated to purchase the services. In most businesses, growth in revenue typically leads to an increase in the accounts receivable balance causing a use of cash as a company grows. Unlike these businesses, our cash position is favorably affected by revenue growth, which results in a source of cash due to our customers prepaying for most of our services.

We have also historically used a portion of our cash for repurchases of our common stock from our stockholders. During the six months ended June 30, 2025 and 2024, we repurchased $300.1 million and $350.0 million (inclusive of $22.5 million in treasury stock then not yet settled), respectively, of our common stock. The repurchase of our common stock was funded using cash from operations. For the six months ended June 30, 2025 and 2024, we also paid dividends of $126.0 million and $111.3 million, respectively.

Financing and Financing Capacity

We had total debt, excluding finance lease liabilities, unamortized discounts and premium, and debt issuance costs of $3,250.0 million and $3,050.0 million at June 30, 2025 and December 31, 2024, respectively, and we were in compliance with our financial and other covenants. The debt at June 30, 2025, primarily consists of senior notes issued in 2025, 2024, 2023, 2020, 2019, and 2015. Interest on the senior notes is payable semi-annually each year. The unamortized discount and debt issuance costs were recorded as "Long-term debt" in the accompanying consolidated balance sheets, and will be amortized to "Interest expense" in the accompanying consolidated statements of operations within this Form 10-Q over the life of the respective senior note. The indenture governing the senior notes restricts our ability to, among other things, create certain liens, enter into sale/leaseback transactions, and consolidate with, sell, lease, convey, or otherwise transfer all or substantially all of our assets, or merge with or into, any other person or entity. We have made, and may from time to time in the future make, optional repayments on our debt obligations, which may include repurchases or exchanges of our outstanding notes, depending on various factors, such as market conditions. Any such repurchases may be effected through privately negotiated transactions, market transactions, tender offers, redemptions or otherwise. See Note 9. for additional information on our financing activities.

We have a $1,000.0 million Syndicated Revolving Credit Facility with Bank of America N.A., HSBC Bank USA, N.A., JP Morgan Chase Bank, N.A., Wells Fargo Bank, N.A., Citibank, N.A., Morgan Stanley Bank, N.A., TD Bank, N.A., Goldman Sachs Bank USA, and the Northern Trust Company with a maturity date of April 5, 2028. Borrowing under the facility is payable at an interest rate of SOFR plus 100.0 to 162.5 basis points, depending on the public debt rating. The financial covenants require that, at the end of any fiscal quarter, we have a consolidated funded debt leverage ratio of less than 3.75 to 1.0_._ At our election, the maximum consolidated funded debt leverage ratio could be permitted to increase to 4.50 to 1.0 (no more than once) and to 4.25 to 1.0 (no more than once) in connection with the closing of a permitted acquisition. The Syndicated Credit Facility may be used for general corporate purposes, including working capital needs and capital expenditures, acquisitions, dividend payments, and the Repurchase Program. As of June 30, 2025, we were in compliance with all financial and other debt covenants under the Syndicated Credit Facility. As of June 30, 2025 and December 31, 2024, the available capacity under the Syndicated Revolving Credit Facility was $995.4 million, which takes into account outstanding letters of credit of $4.6 million.

Cash Flow

The following table summarizes our cash flow data:

Three Months EndedSix Months Ended
June 30,June 30,
20252024Percentage change20252024Percentage change
(in millions)(in millions)
Net cash provided by operating activities$244.5$211.715.5%$689.2$592.416.3 %
Net cash (used in) provided by investing activities$(80.6)$56.1N/A$(138.4)$(23.8)481.5 %
Net cash (used in) provided by financing activities$(659.0)$14.1N/A$(225.7)$(236.9)(4.7)%

Operating Activities

Net cash provided by operating activities was $244.5 million for the three months ended June 30, 2025, compared to $211.7 million for the three months ended June 30, 2024, an increase of $32.8 million or 15.5%. The increase in operating cash flow was due to an increase in operating profit partially offset by the timing of certain cash payments throughout the quarter.

Net cash provided by operating activities was $689.2 million for the six months ended June 30, 2025, compared to $592.4 million for the six months ended June 30, 2024, an increase of $96.8 million or 16.3%. The increase in operating cash flow was due to an increase in operating profit and a federal tax refund received in the first quarter of 2025.

Investing Activities

Net cash used in investing activities of $80.6 million for the three months ended June 30, 2025 was primarily related to capital expenditures of $55.8 million and acquisitions of $20.3 million. Net cash provided by investing activities of $56.1 million for the three months ended June 30, 2024 was primarily related to proceeds received upon settlement of our retained interests related to the prior sales of our healthcare business in 2016 and our specialized markets business in 2022 of $112.1 million, partially offset by capital expenditures of $57.8 million.

Net cash used in investing activities of $138.4 million for the six months ended June 30, 2025 was primarily related to capital expenditures of $109.5 million and an acquisition and purchase of an additional controlling interest of $24.4 million. Net cash used in investing activities of $23.8 million for the six months ended June 30, 2024 was primarily related to capital expenditures of $113.0 million, and acquisitions and a purchase of an additional controlling interest totaling $23.4 million, partially offset by proceeds received upon settlement of our retained interests related to the prior sales of our healthcare business in 2016 and our specialized markets business in 2022 of $112.1 million.

Financing Activities

Net cash used in financing activities of $659.0 million for the three months ended June 30, 2025 was primarily driven by the repayment of our 2025 senior note of $500.0 million, repurchases of common stock of $100.0 million, dividends paid of $63.0 million, payment of excise tax of $7.6 million, the net share settlement of taxes from restricted stock and performance share awards of $7.6 million, and other financing activities of $3.7 million, partially offset by the proceeds from stock options exercised of $22.9 million. Net cash provided by financing activities of $14.1 million for the three months ended June 30, 2024 was primarily driven by the payment on early extinguishment of debt of $396.4 million, the funding of a $150.0 million accelerated share repurchase program, and dividends paid of $55.5 million, partially offset by proceeds from the issuance of long-term debt, net of original discount, of $590.2 million, and proceeds from stock options exercised of $35.0 million.

Net cash used in financing activities of $225.7 million for the six months ended June 30, 2025 was primarily driven by the repayment of our 2025 senior note of $500.0 million, repurchases of common stock of $300.1 million, dividends paid of $126.0 million, the net share settlement of taxes from restricted stock and performance share awards of $25.5 million, payment of excise tax of $7.6 million, payment of debt issuance costs of $6.2 million, and other financing activities of $6.2 million, partially offset by the proceeds from issuance of long term debt of $698.3 million and proceeds from stock options exercised of $47.6 million. Net cash used in financing activities of $236.9 million for the six months ended June 30, 2024 was primarily driven by the payment on the early extinguishment of debt of $396.4 million, the funding of $350.0 million of accelerated share repurchase programs, and dividends paid of $111.3 million, partially offset by proceeds from the issuance of long-term debt, net of original discount, of $590.2 million, and proceeds from stock options exercised of $63.2 million.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

Contractual Obligations

There have been no material changes to our contractual obligations outside the ordinary course of our business from those reported in our annual report on Form 10-K and filed with the Securities and Exchange Commission on February 26, 2025.

Critical Accounting Estimates

Our management’s discussion and analysis of financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements require management to make estimates and judgments that affect reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the dates of the financial statements and revenue and expenses during the reporting periods. These estimates are based on historical experience and on other assumptions that are believed to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, including those related to acquisition purchase price allocations, revenue recognition, goodwill and intangible assets, pension and other postretirement benefits, stock-based compensation, income taxes, and allowance for doubtful accounts. Actual results may differ from these assumptions or conditions. Some of the judgments that management makes in applying its accounting estimates in these areas are discussed under the heading "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in our annual report on Form 10-K dated and filed with the Securities and Exchange Commission on February 26, 2025. Since the date of our annual report on Form 10-K, there have been no material changes to our critical accounting policies and estimates other than the items noted below.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

| --- | --- |

Market risks at June 30, 2025 have not materially changed from those discussed under Item 7A in our annual report on Form 10-K dated and filed with the Securities and Exchange Commission on February 26, 2025.

Item 4. Controls and Procedures

| --- | --- |

Disclosure Controls and Procedures

We are required to maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives at the reasonable assurance level.

Our management, with the participation of the Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this quarterly report on Form 10-Q. Based upon the foregoing assessments, our Chief Executive Officer and Chief Financial Officer have concluded that, as of June 30, 2025, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

During the six months ended June 30, 2025, there has been no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings | --- | --- |

We are party to legal proceedings with respect to a variety of matters in the ordinary course of business. See Part I Item 1. Note 15. to our condensed consolidated financial statements for the six months ended June 30, 2025 for a description of our significant current legal proceedings, which is incorporated by reference herein.

Item 1A. Risk Factors

| --- | --- |

There has been no material change in the information provided under the heading “Risk Factors” in our annual report on Form 10-K dated and filed with the Securities and Exchange Commission on February 26, 2025, as supplemented by the information provided under the heading "Risk Factors" in our Form 10-Q for the quarter ended June 30, 2025.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | --- | --- |

Recent Sales of Unregistered Securities

We did not have any unregistered sales of equity securities during the period covered by this report.

Issuer Purchases of Equity Securities

Under the Repurchase Program, we may repurchase stock in the market or as otherwise determined by us. These authorizations have no expiration dates and may be suspended or terminated at any time. On February 19, 2025, our Board of Directors approved an additional share repurchase authorization of up to $1.0 billion. As of June 30, 2025, we had $1,291.5 million available to repurchase shares. Our share repurchases for the quarter ended June 30, 2025 are set forth below:

PeriodTotal Number of Shares PurchasedAverage Price Paid per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or ProgramsApproximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs
(in millions)
April 1, 2025 through April 30, 2025123,766(1)$288.09123,766$1,391.5
May 1, 2025 through May 31, 2025270,399(2)$314.35270,399$1,291.5
June 1, 2025 through June 30, 202552,614(2)$309.5852,614$1,291.5
446,779446,779
(1)In March 2025, we entered into an ASR agreement to repurchase shares of our common stock for an aggregate purchase price of $200.0 million with Citibank, N.A. This ASR agreement is accounted for as a treasury stock transaction and a forward stock purchase agreement indexed to our common stock. Upon the payment of the aggregate purchase price on March 11, 2025, we received an initial delivery of 570,470 shares of our common stock at an initial price of $298.00 per share, representing an initial delivery of approximately 85 percent of the aggregate purchase price. Upon the final settlement of this ASR agreement in April 2025, we received 123,766 additional shares, as determined based on the volume weighted average share price of our common stock, less a discount, of $288.09 per share during the term of this ASR agreement.
(2)In May 2025, we entered into an additional ASR agreement to repurchase shares of our common stock for an aggregate purchase price of $100.0 million with Goldman Sachs & Co. LLC. This ASR agreement is accounted for as a treasury stock transaction and a forward stock purchase agreement indexed to our common stock. Upon the payment of the aggregate purchase price on May 20, 2025, we received an initial delivery of 270,399 shares of our common stock at an initial price of $314.35 per share, representing an initial delivery of approximately 85 percent of the aggregate purchase price. Upon the final settlement of this ASR agreement in June 2025, we received 52,614 additional shares, as determined based on the volume weighted average share price of our common stock, less a discount, of $309.58 per share during the term of this ASR agreement.

Item 3. Defaults Upon Senior Securities | --- | --- |

None.

Item 4. Mine Safety Disclosures | --- | --- |

None.

Item 5. Other Information

| --- | --- |

Rule 10b5-1 and Non-Rule 10b5-1 Trading Arrangements

During the fiscal quarter ended June 30, 2025, none of our Section 16 officers or directors adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangements” (as those terms are defined in Item 408 of Regulation S-K of the Exchange Act).

Item 6. Exhibits

| --- | --- |

See Exhibit Index.

EXHIBIT INDEX

Exhibit NumberDescription
3.1Restated Certificate of Incorporation of Verisk Analytics, Inc., effective as of May 20, 2025, incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K dated May 27, 2025.
3.2Amended and Restated Bylaws of Verisk Analytics, Inc., effective as of May 20, 2025, incorporated by herein by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K dated May 27, 2025.
31.1Certification of the Chief Executive Officer of Verisk Analytics, Inc. pursuant to Rule 13a-14 under the Securities Exchange Act of 1934.*
31.2Certification of the Chief Financial Officer of Verisk Analytics, Inc. pursuant to Rule 13a-14 under the Securities Exchange Act of 1934.*
32.1Certification of the Chief Executive Officer and Chief Financial Officer of Verisk Analytics, Inc. pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of Sarbanes-Oxley Act of 2002.*
101.INSInline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.*
101.SCHInline XBRL Taxonomy Extension Schema.*
101.CALInline XBRL Taxonomy Extension Calculation Linkbase.*
101.DEFInline XBRL Taxonomy Definition Linkbase.*
101.LABInline XBRL Taxonomy Extension Label Linkbase.*
101.PREInline XBRL Taxonomy Extension Presentation Linkbase.*
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).*
*Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Verisk Analytics, Inc.
(Registrant)
Date: July 30, 2025By:/s/ Elizabeth D. Mann
Elizabeth D. Mann
Chief Financial Officer
(Principal Financial Officer and Duly Authorized Officer)